The Heart Center, Rigshospitalet, Copenhagen, Denmark.
EuroIntervention. 2017 Oct 13;13(9):e1058-e1066. doi: 10.4244/EIJ-D-17-00147.
This study aimed to assess survival and causes of death in a real-world TAVR population as compared to an age- and sex-matched background population.
Each aortic stenosis (AS) patient treated with TAVR in Eastern Denmark between 2007 and 2014 (n=617) was matched with 25 age- and sex-matched controls (n=15,425) randomly drawn from the general Danish population. In the total TAVR population, early mortality (≤90 days) was significantly higher (hazard ratio [HR] 3.90 [2.82-5.39]; p<0.001) as compared to its background population, driven mainly by cardiovascular (CV) mortality. Late mortality (>90 days) was not different between the TAVR and background population (HR 1.16 [0.96-1.40]; p=0.126), causes of death being mainly non-CV. In subgroup analysis, the HR for late mortality was 0.98, 1.11, and 1.90 for the low-, intermediate-, and high-risk TAVR groups, respectively, as compared to their matched controls and 1.04, 1.45, and 1.52 for the high gradient, paradoxical low-flow low-gradient (P-LFLG), and classical LFLG (C-LFLG) groups, respectively, as compared to their controls.
In general, AS patients who survive the first three months after TAVR have a similar survival to their matched controls. Relative survival benefit is the highest in low-to-intermediate risk AS patients with a high transvalvular gradient.
本研究旨在评估真实世界中经导管主动脉瓣置换术(TAVR)人群的生存率和死亡原因,并与年龄和性别匹配的背景人群进行比较。
在丹麦东部,2007 年至 2014 年间接受 TAVR 治疗的每位主动脉瓣狭窄(AS)患者(n=617)均与 25 名年龄和性别匹配的背景人群(n=15425)随机匹配。在整个 TAVR 人群中,早期死亡率(≤90 天)显著较高(风险比 [HR] 3.90 [2.82-5.39];p<0.001),主要归因于心血管(CV)死亡率。晚期死亡率(>90 天)在 TAVR 和背景人群之间无差异(HR 1.16 [0.96-1.40];p=0.126),死亡原因主要为非 CV 原因。亚组分析显示,与低、中、高风险 TAVR 组的匹配对照组相比,晚期死亡率的 HR 分别为 0.98、1.11 和 1.90,与高梯度、反常低流量低梯度(P-LFLG)和经典低流量低梯度(C-LFLG)组的匹配对照组相比,HR 分别为 1.04、1.45 和 1.52。
总体而言,TAVR 后三个月存活的 AS 患者的生存率与匹配对照组相似。在具有高跨瓣梯度的低至中危 AS 患者中,相对生存获益最高。